CHICAGO, USA: ICAP Patent Brokerage, a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm, is offering for sale next generation LOAC device technology from global electronics and electrical engineering leader Siemens AG. The available patent portfolio comprises over 200 assets including 18 issued US patents.
This award winning biochip technology was jointly developed by Siemens, Fraunhofer Institute for Silicon Technology, and Infineon Technologies and won the German Future Prize in 2004.
Siemens' Lab-on-a-Chip portfolio addresses market limitations by disclosing techniques for:
* Manufacturing cost-effective sensor arrangements with diverse applications in fields such as medical diagnosis, environmental analysis, food analysis, and pharmacology.
* Detecting nucleotide sequences (DNA/RNA) using electrophoresis, SNP analysis, isolation of magnetic beads, and PCR thermocycling for sensor applications.
* Extracting and analyzing a smear sample of complete DNA or protein via microfluidic systems.
"We are privileged to represent Siemens in the sale of this groundbreaking LOAC patent portfolio. Siemens' research contribution to this field is significant and this portfolio represents an attractive acquisition opportunity for a number of market players," said Cameron Gray, SVP at ICAP Patent Brokerage.